Search results
Results from the WOW.Com Content Network
(Reuters) - Japan's Astellas Pharma said on Monday the U.S. Food and Drug Administration (FDA) has declined to approve its experimental drug to treat a type of gastric cancer, citing issues ...
Japan-based Astellas Pharma Inc (OTC: ALPMF) (OTC: ALPMY) announced a strategic investment to support the advancement of Taysha Gene Therapies Inc's (NASDAQ: TSHA) adeno-associated virus (AAV ...
Rating Action: Moody's downgrades Astellas' rating to A3; outlook stableGlobal Credit Research - 23 Mar 2021Tokyo, March 23, 2021 -- Moody's Japan K.K. has downgraded the issuer rating of Astellas ...
Astellas Pharma office in Canada. Astellas Pharma Inc. (アステラス製薬株式会社, Asuterasu Seiyaku Kabushiki-gaisha) is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. (山之内製薬株式会社, Yamanouchi Seiyaku Kabushiki-gaisha) and Fujisawa Pharmaceutical Co., Ltd. (藤沢薬品工業株式会社 ...
This page was last edited on 12 January 2025, at 17:05 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
OSI Pharmaceuticals, Inc. was an American pharmaceutical company formerly based in Long Island, New York with facilities in Colorado, New Jersey and the United Kingdom. On Sunday, May 16, 2010 OSI agreed to be acquired by Japan-based, TSE-listed Astellas Pharma for $4.0 billion. [4] The deal was closed on June 9, 2010.
The U.S. government, late last month, selected the first 10 drugs, including the top-selling blood thinner Eliquis from Bristol Myers Squibb and Pfizer, which will face price negotiations as part ...
Ipragliflozin, jointly developed by Astellas Pharma and Kotobuki Pharmaceutical, was approved in Japan on January 17, 2014, [3] and in Russia on May 22, 2019. [4] Ipragliflozin is a Sodium/glucose cotransporter 2 (SGLT2) inhibitor . [5] These membrane proteins are on the cell surface and transfer glucose into the cells.